She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.

At the age of 21,[4] Haurwitz began working as a graduate student in Jennifer Doudna's laboratory, in 2008 where she completed her doctorate in molecular and cell biology.

[5] Haurwitz originally intended on becoming an intellectual property lawyer for biotechnology patents but later chose to continue in science.

[9] Its researchers explore issues in antimicrobial resistance, food scarcity, and vaccine shortages.

[10] In 2018, Haurwitz announced that the firm was shifting focus on medicine and developing cancer therapies targeting microbes.